Document:

<PAGE>

                                                                   Exhibit 10.13

                                    AGREEMENT
                               DATED MARCH 8, 1999

     This agreement (the "AGREEMENT"), entered into as of November 1, 1998, by
and between Spectra Science Corporation, a Delaware corporation having its
principal place of business at 155 South Main Street, Suite 101, Providence,
Rhode Island 02903 (hereinafter referred to as "SPECTRA"), and Crane & Co.,
Inc., a Massachusetts corporation having its principal place of business at 30
South Street, Dalton, Massachusetts 01226 (hereinafter referred to as "CRANE").
SPECTRA and CRANE are jointly referred to in the present Agreement as the
"Parties" and individually as a "Party".

                              W I T N E S S E T H:

     WHEREAS, SPECTRA has developed, and has exclusive worldwide proprietary
rights in and to certain PATENTS (as defined herein), and IMPROVEMENTS and KNOW
HOW relating thereto (the "TECHNOLOGIES"), which allow for [***];

     WHEREAS, CRANE has participated over the past two years and will continue
to participate on an ongoing basis as the Parties may agree in (i) addressing
manufacturing issues associated with incorporating the TECHNOLOGIES into
security papers; (ii) validating SPECTRA's products for [***]; and (iii)
providing consulting and technical services and technical know-how ("CRANE's
KNOW-HOW") [***] involved in the design and issuance of secure documents;

     WHEREAS, in consideration of the foregoing services received and to be
received, SPECTRA desires to pay to CRANE a fee for such services and CRANE's
KNOW-HOW; and

     WHEREAS, the Parties also desire that all negotiations with [***] (or with
any of their vendors, suppliers, or agents) with respect to the TECHNOLOGIES
shall henceforth be conducted by SPECTRA; that SPECTRA has the final authority
to negotiate terms and conditions for the TECHNOLOGIES; and, further, that all
MATERIALS, as defined in Article 2.1 of this AGREEMENT, to be used in any
substrates by [***] (or by any of its vendors, suppliers, or agents including
but not limited to CRANE) shall be supplied directly by SPECTRA;

     NOW, THEREFORE, in consideration of the mutual promises and covenants set
forth herein, the sufficiency of which is hereby acknowledged, the Parties
hereto agree as follows:

                                   DEFINITIONS

     The Parties agree to the following definitions for purposes of this
AGREEMENT:

     .    PATENT or PATENTS means the patents and patent application pertaining
          to

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

                                       1

<PAGE>

          [***] including any and all divisions, continuations,
          continuations-in-part, extensions, substitutions, renewals,
          confirmations, supplementary protection certificates, registrations,
          revalidations, reissues or additions of or to any of the aforesaid
          patents and patent applications, and any foreign counterparts to any
          of the foregoing.

     .    IMPROVEMENT or IMPROVEMENTS means all enhancements or modifications
          made by SPECTRA, to methods or products described in the PATENTS
          which, if used or applied by another party, would infringe one or more
          claims of an issued PATENT.

     .    SPECTRA's KNOW-HOW means all technical information data and
          intellectual property rights of SPECTRA, relating to the use of
          PATENTS or IMPROVEMENTS including existing intellectual property of
          SPECTRA, for the purposes consistent with this AGREEMENT.

                                   ARTICLE ONE

     In the event that Crane is awarded a [***] contract that requires the use
of the TECHNOLOGIES, SPECTRA shall grant to CRANE a non-exclusive right to use
the TECHNOLOGIES for purposes consistent with the performance of CRANE's
obligations under this AGREEMENT and to incorporate MATERIALS containing said
TECHNOLOGIES into substrates manufactured by CRANE for sale to or use by [***].
It is understood that the rights granted to CRANE herein do not include the
right to make MATERIAL containing TECHNOLOGIES.

                                   ARTICLE TWO

     2.1 The Parties acknowledge and agree that from the date hereof, all
negotiations with [***] (or with any of their vendors, suppliers, or agents)
with respect to the TECHNOLOGIES shall henceforth be conducted by SPECTRA; that
SPECTRA has the final authority to negotiate pricing for the MATERIALS and
TECHNOLOGIES; and, further, that all MATERIALS to be used in any substrates by
[***] or by any of their vendors, suppliers, or agents (including but not
limited to CRANE) shall be supplied directly by SPECTRA. "MATERIALS" shall mean
all materials incorporating TECHNOLOGIES and containing [***].

     2.2 In acknowledgement for and in consideration of CRANE's services to (i)
address manufacturing issues associated with incorporating the TECHNOLOGIES into
security papers, (ii) validate SPECTRA's products for [***] and (iii) providing
CRANE's KNOW-HOW to facilitate the incorporation of the TECHNOLOGIES into
products for [***] involved in the design and issuance of secure documents,
SPECTRA agrees to pay to CRANE fees as follows:

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

                                       2

<PAGE>

          (a)(1)(A) SPECTRA agrees to pay CRANE a fee of [***] of which is
payable by or before [***]. The balance of $[***] shall be paid by SPECTRA to
CRANE on or before the due date of the first fixed payment determined as set
forth in Section 2.2(a)(1)(B) below. The Parties shall determine the fee to be
paid to CRANE on an annual basis in accordance with the following fee adjustment
formula.

          (a)(1)(B) The Parties shall determine a fixed fee to be paid to CRANE
on an annual basis (within 90 days after the end of the calendar year to which
the fee relates), for each year following the first year in which SPECTRA
receives revenues from [***] in connection with the sale of MATERIALS
for use in [***]. The fixed fee for any year shall be determined
as follows:

               (i)  [***] multiplied by

               (ii) an amount equal to revenues actually received by SPECTRA
                    from [***] in the preceding year on account of sale
                    of MATERIALS for use in [***], less SPECTRA's actual fully
                    loaded costs (defined as direct labor, direct material, and
                    allocable indirect costs in accordance with Generally
                    Accepted Accounting Principles and such other accounting
                    principles or regulations as may apply, including SPECTRA's
                    incurred independent research & development costs required
                    in order to develop, at the request of [***] new "codes"/1/
                    for MATERIALS other than the [***] currently developed) of
                    MATERIALS supplied to [***] for the preceding year for use
                    [***] plus a [***] markup on fully loaded costs.

          (a)(2) In the event that the [***] terminates all use of the
TECHNOLOGIES in [***], and Spectra receives no further revenue from sales of
MATERIALS after such termination, no fees shall be due to Crane for any period
after such termination.

          (b)(1) In the event that a [***] agrees to purchase directly from
CRANE any paper or substrate (excluding [***]) containing the MATERIALS, then
SPECTRA agrees to and shall supply CRANE with all MATERIALS required for use in
the manufacture and/or sale of such [***]. SPECTRA and CRANE shall in each such
case negotiate in good faith and agree to (i) a paper price per pound quote (the
"QUOTE") which reflects the added value of the MATERIALS (including SPECTRA's
cost to manufacture the MATERIALS) and the TECHNOLOGIES and (ii) the
differential amount (the "DIFFERENTIAL") of the QUOTE associated with the
TECHNOLOGIES, the MATERIALS, and inclusion of the MATERIALS in the paper or
substrate. CRANE agrees to provide all information in its possession or
reasonably available to it

----------
/1/ A "code" is a unique combination of wavelengths emitted from MATERIALS
incorporated in a substrate. The entire amount of the above-described
independent research & development costs for any year for purposes of this
section 2.2(a)(1)(B)(ii) shall not exceed [***].

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

                                       3

<PAGE>

to assist SPECTRA in their joint effort of calculating the QUOTE and the
DIFFERENTIAL, including but not limited to previous contract prices for similar
paper or substrate lacking the TECHNOLOGIES and the MATERIALS and any
information as to comparable prices of other suppliers. No quote will be
submitted for paper or substrate containing materials without mutual agreement
by CRANE and SPECTRA on the amount of the DIFFERENTIAL.

          (b)(2) CRANE and SPECTRA agree to negotiate in good faith the price at
which SPECTRA will provide the MATERIALS, to be paid after delivery of the paper
or substrate to [***].

          (b)(2)(i) The parties shall negotiate a fixed price for Crane to pay
                    to Spectra for the first year in which the event in (b)(1)
                    occurs. That negotiated fixed price shall be the product of:

                    (A)  the estimated DIFFERENTIAL for the first year;

                    (B)  the estimated pounds of paper to be provided by Crane
                         to [***] during the first year; and

                    (C)  a factor of [***]

          (b)(2)(ii) For any subsequent year in which the event in(b)(1) occurs,
                    the Parties shall determine such year's fixed price by using
                    the formula in (b)(2)(i), substituting the preceding year's
                    actual DIFFERENTIAL in (A), and actual pounds of paper
                    provided by CRANE in (B).

     2.3 Spectra agrees to keep accurate books and records in sufficient detail
to enable the terms of this AGREEMENT to be satisfactorily performed. Spectra
shall permit an independent public accountant designated by CRANE, upon CRANE's
prior written request (given reasonably in advanced under the circumstances) and
at CRANE's expense, to have access during normal business hours to its books and
records as may be reasonably necessary to verify satisfactory performance of
this AGREEMENT. Such access to books and records shall occur not more than once
each fiscal year of SPECTRA.

                                 ARTICLE THREE

     3.1 The Parties each recognize and hereby acknowledge that in the
performance of this AGREEMENT, each Party and its employees and/or agents may
have access to secret or proprietary information owned and controlled by the
other Party ("CONFIDENTIAL INFORMATION"). The Parties agree that all such
CONFIDENTIAL INFORMATION acquired by one Party (hereinafter "the receiving
Party") shall remain the disclosing Party's exclusive property and the receiving
Party shall keep and have its employees and/or agents keep any and all such
information confidential and shall not copy or publish or disclose it to others
or authorize its employees, agents, or anyone else to copy, publish or disclose
it to others, without the disclosing Party's prior written approval.

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

                                       4

<PAGE>

     3.2 All CONFIDENTIAL INFORMATION in tangible form shall be returned to the
disclosing Party upon request or upon termination of this AGREEMENT.

     3.3 The obligations and provisions of this Article Three shall survive
Termination of this AGREEMENT.

                                  ARTICLE FOUR

     4.1 This AGREEMENT shall commence on the date hereof and shall terminate
fifteen (15) years from the date [***] commences the use of the TECHNOLOGIES in
[***], but in no event shall this Agreement extend more than twenty (20) years
from the date hereof (the "TERM"), unless earlier terminated in accordance with
Section 4.2 hereof. SPECTRA further agrees to enter into good faith negotiations
with CRANE to renegotiate another agreement after this AGREEMENT has expired.

     4.2 If either SPECTRA, on the one hand, or CRANE, on the other hand, shall
be in default of any material obligation hereunder or shall be adjudged
bankrupt, or become insolvent, or make an assignment for the benefit of
creditors, or be placed in the hands of a receiver or a trustee in bankruptcy,
the other Party may terminate this AGREEMENT by giving sixty (60) days' notice
to the first Party, specifying the basis for termination. If within sixty (60)
days after the receipt of such notice, the Party receiving it shall remedy the
condition forming the basis for termination, such notice shall cease to be
operative and this AGREEMENT shall continue in full force.

     4.3 Termination or expiration of this AGREEMENT for any reason will not
affect (i) SPECTRA's intellectual property rights with respect to the
TECHNOLOGIES and (ii) the parties' confidentiality obligations under Article III
hereof, which shall survive termination or expiration.

                                  ARTICLE FIVE

     5.1 Dispute Resolution. In the event of any controversy or claim arising
out of or relating to any provision of this AGREEMENT or the breach thereof, the
Parties shall try to settle their differences amicably between themselves. Any
such controversy or claim which the Parties are unable to resolve shall
initially be submitted for review and resolution by the Chief Executive Officers
of SPECTRA and CRANE prior to the initiation by either Party of any legal
action.

     5.2 Severability. If any part, term, or provision of this AGREEMENT shall
be found invalid or unenforceable under any valid controlling law, the AGREEMENT
shall be construed as if the invalid or unenforceable provisions had been
deleted, and the AGREEMENT shall be deemed modified to the extent necessary to
render the surviving provisions enforceable to the fullest extent permitted by
law. In the event the legality of any provision of this AGREEMENT is otherwise
brought into question because of a decision by a court of competent
jurisdiction, SPECTRA, on the one hand, or CRANE, on the other hand, by written
notice to and agreement with the other Party, may revise the provision in
question or may delete it entirely so as to comply with the decision of the
court.

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

                                       5

<PAGE>

     5.3 Governing Law. This AGREEMENT shall be construed and governed according
to the laws of the Commonwealth of Massachusetts. The courts and authorities of
the Commonwealth of Massachusetts shall have exclusive jurisdiction over all
controversies that may arise under or in relation to this AGREEMENT and the
execution and interpretation thereof and compliance therewith.

     5.4 Force Majeure. Neither Party shall be responsible to the other for any
failure or delay in performing any of its obligations under this AGREEMENT if
such delay or nonperformance is caused by strike, labor stoppage, lockout or
other labor trouble, fire, flood, accident, act of God or of the Government, or
by other cause unavoidable or beyond the control of such Party, provided that
prompt notice is given of the cause of the delay or nonperformance and diligent
continuing efforts are made to resume performance.

     5.5 Nonassignability. This AGREEMENT shall not be assignable by either
Party hereto, except to a wholly-owned subsidiary or to a successor to all or
substantially all of such Party's business, without the prior written consent of
the other Party.

     5.6 Entire Agreement; Modification. This AGREEMENT constitutes the entire
understanding between the Parties hereto with respect to the subject matter
hereof. In particular, this AGREEMENT supercedes that certain Patent License
Agreement dated as of March 1, 1997, by and between SPECTRA and CRANE, as that
Agreement was amended by 1etter from SPECTRA to CRANE dated as of June 23, 1998
(as so amended, the "Prior Agreement"), which Prior Agreement is hereby
terminated. No modification or amendment hereof shall be valid or binding upon
the Parties hereto unless made in writing and duly executed on behalf of both
Parties.

     5.7 Waiver. No actual waiver of breach or default by a Party of any
provision of this AGREEMENT shall be deemed or construed to be a waiver of any
succeeding breach or default of the same or any other provision.

     5.8 Notices. Notices, where permitted or required hereunder, shall be
sufficiently given if sent by Certified Mail, return receipt requested and
postage prepaid, or if delivered by hand, if sent by facsimile transmission with
a copy deposited in the U.S. mails, first class and postage prepaid, or if sent
by overnight courier:

If to SPECTRA, to:   SPECTRA SCIENCE CORPORATION
                     55 South Main Street, Suite 101
                     Providence, RI 02903
                     Attention: President

with a copy to:

                     Kenneth S. Boger, Esquire
                     Warner & Stackpole LLP
                     75 State Street
                     Boston, MA 02109

                                       6

<PAGE>

If to CRANE, to:

                     CRANE & CO. INC.
                     30 South Street
                     Dalton, MA 01226
                     Attention: President

with a copy to:

                     Stephen D. Knight, Attorney at Law
                     Kirkland & Ellis
                     655 Fifteenth Street, N.W.
                     Washington, D.C. 20005-5793

Notices so given shall be deemed to have been received by the addressee on the
fourth day after deposit as Certified Mail, on the day after dispatch by
overnight courier, and on the day of delivery by hand or the day of transmittal
by facsimile transmission.

                                       7

<PAGE>

     IN WITNESS WHEREOF, the Parties hereby execute this Agreement, in
triplicate, through the representatives listed below:

ACCEPTED AND AGREED TO BY:

SPECTRA SCIENCE CORPORATION                  CRANE & CO., INC.
155 South Main Street                        30 South Street
Providence, RI 02903                         Dalton, MA 01226

By /s/ Nabil M. Lawandy                      By /s/ Illegible
   --------------------                         ------------------
   Nabil M. Lawandy                             CFO
   President & CEO

Date Signed: 3/8/99                          Date Signed: 3/8/99

                                       8<PAGE>

                                                                   Exhibit 10.14

                       MARKETING AND DISTRIBUTION AGREEMENT

     This Marketing and Distribution Agreement (the "Agreement") is dated as of
April 9, 2001 between Spectra Science Corporation ("Spectra") with an office at
321 South Main Street, Providence RI 02903 and Kleen-Tex Industries, Inc.
("Kleen-Tex") with an office at By-Pass Road, LaGrange, GA 30241.

     WHEREAS, Kleen-Tex produces mats, mops, and certain other dust control
products ("Mats") for the commercial textile services industry and other
commercial markets.

     WHEREAS, Spectra has developed, manufactures and markets LaserCode(TM)
labels ("LaserCode") and associated LaserCode(TM) readers ("Readers") employing
optical based labeling technology proprietary to Spectra to produce
machine-readable label applications in garments and Mats; and

     WHEREAS, Kleen-Tex wishes to obtain the right and license to apply the
LaserCode labels to Mats, to sell and distribute the same, and to cooperate with
Spectra in the promotion and marketing of LaserCode technology;

     NOW, THEREFORE, for the mutual promises set forth herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereby agree as follows:

1. Grant of License. Subject to all of the terms and conditions set forth in
this Agreement, Spectra hereby grants Kleen-Tex, for the Term of this Agreement,
a license, exclusive on a worldwide basis with respect to identification of Mats
used for dust control purposes (the "Field"), to market, distribute, and sell
LaserCode labels separately to other manufacturers of mats or in combination
with and applied to Mats. Other than the license hereby granted, all
intellectual property rights with respect to LaserCode 1abels, Readers, or any
other LaserCode technology, including any improvements to the same, regardless
of by whom developed, shall remain the property of Spectra.

2. Minimum Purchase Obligations of Kleen-Tex. During each calendar year of the
Term, Kleen-Tex shall purchase from Spectra a minimum of [***] LaserCode labels
and [***] ink cartridges for application to a minimum of [***] square meters of
graphic and or other types of Mats for the purpose of mat identification.

3. Pricing and Payments; Shipments.

     a. Purchases shall be made in units of [***] cartridges and [***] 1abels (a
"Unit") at a combined cost of [***] per Unit.

     b. All prices are F.O.B. Spectra's manufacturing facility. Kleen-Tex shall
be responsible for freight charges.

     c. Payment to Spectra shall be net thirty (30) days after date of shipment.
All payments are to be made in full, on the due date, in United States dollars,
to Spectra at the

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

<PAGE>

address shown on the first page of this Agreement in immediately available
funds, with interest at the rate of one and one-half percent (1 1/2%) per month
on any overdue payments.

     d. Shipment of LaserCode labels by Spectra to Kleen-Tex shall be made only
against written orders issued by Kleen-Tex ("Orders"). In the event of any
conflict between the terms of an Order and this Agreement, this Agreement shall
take precedence. The delivery date for LaserCode labels to be shipped under this
Agreement shall be specified by Kleen-Tex in each Order. Each Order shall
specify the exact number of Units to be delivered and shall specify a delivery
date which shall be at least 20 business days after the date of receipt by
Spectra of the Order.

     e. If, in the sole judgment of Spectra, the financial condition of
Kleen-Tex at any time does not justify continuation of production or delivery on
the terms of payment specified herein, Spectra may require full or partial
payment on any Order in advance, and in addition, in the event that any
proceeding is brought by or against Kleen-Tex under any bankruptcy or insolvency
laws, the license hereunder shall terminate, and Spectra shall be entitled to
cancel any Orders then outstanding.

4. Certain Obligations of Spectra.

     a. Spectra shall sell [***] Reader to Kleen-Tex for quality control
applications at one-half of Spectra's cost. Freight charges associated with
delivery of the same to Kleen-Tex shall be additional and shall be for
Kleen-Tex's account. Spectra shall provide at no additional charge a reasonable
amount of technical assistance as needed with respect to the Reader to Kleen-Tex
personnel by telephone and e-mail during normal business hours during the Term
of the Agreement.

     b. Spectra shall sell Kleen-Tex a printing system for printing LaserCode
labels at Kleen-Tex's LaGrange, Georgia facility for a total price of [***],
which shall include a personal computer, printer, and software. Freight charges
associated with delivery of the same to Kleen-Tex shall be additional and shall
be for Kleen-Tex's account. Spectra shall provide at no additional charge a
reasonable amount of technical assistance as needed with respect to the printing
system to Kleen-Tex personnel by telephone and e-mail during normal business
hours during the Term of the Agreement.

     c. Spectra shall sell Readers to Kleen-Tex at an agreed to price and volume
schedule at the time of purchase for direct use or OEM resale to Kleen-Tex
customers and its competitors.

Spectra shall recommend Kleen-Tex products for customer applications as in its
sole discretion it deems appropriate and feasible.

     d. For the Term of the agreement, Kleen-Tex shall have the right to sell
LaserCode labels and Readers to other manufacturers and distributors of Mats.

     e. Spectra shall provide brochures and sales materials for Clean '01 and
other promotions as needed, in such quantities and containing such content as
Spectra deems appropriate and feasible.

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

                                       2

<PAGE>

     f. Kleen-Tex Japan shall apply for a patent in Japan and a United States
patent with respect to the applied use of Spectra's proprietary LaserCode
technology to Mats, and Spectra agrees to provide technical assistance with
respect to such application. It is hereby acknowledged that Kleen-Tex Japan
shall own such patent but agrees to grant a royalty-free exclusive (including as
to Spectra) license to Kleen-Tex under such patent with respect to the Field
during the term of such patent, subject to the provisions of Section 7 hereof.

5. Exclusivity. During the Term, Kleen-Tex shall be the worldwide exclusive
distributor of labels for Mats employing LaserCode technology[, and Spectra
shall be Kleen-Tex's exclusive supplier of optic automatic identification
technology for Mats.] It is understood that Kleen-Tex applies printed labels and
radio frequency chips to mats upon customer request.

6. Marketing.

     a. The parties shall participate jointly in preparing and releasing a
marketing announcement, the content of which shall be subject to the approval of
both parties, with respect to their collaborative efforts to market LaserCode
technology.

     b. Kleen-Tex's exclusive marketing rights are conditioned upon Kleen-Tex's
best efforts to promote and market the LaserCode technology in connection with
the Mats. "Best efforts" for the purpose of this agreement is defined to mean
mention of the avalability of LaserCode labels in trade publications, operation
of a pilot demonstration unit in Kleen-Tex facilities and inclusion of this
pilot unit in plant tours for customers as well as promotion of the system in
training seminars and at trade shows.

     c. The Mats on which LaserCode labels have been applied shall be marketed
on a joint logo basis in the trade press of Kleen-Tex with specific reference to
Spectra and LaserCode(TM). KleenTex shall furnish to Spectra, prior to
dissemination of any labels, product literature, or marketing material,
representative copies of the same showing proper use or display of the Spectra
name and trademark(s). Kleen-Tex shall make such changes as Spectra requests to
ensure proper use of Spectra's name and trademark(s) and to avoid any statement
that is, in Spectra's business judgment, inaccurate, objectionable or
misleading. Kleen-Tex shall not have the right to use Spectra's name or
trademarks except in connection with marketing and selling Mats containing the
LaserCode technology.

7. Term and Termination.

     a. Term of this agreement will be five (5) years with automatic roll over
for additional five (5) years unless terminated according to one of the
following provisions.

     b. Spectra may, at its discretion, terminate this Agreement or the
exclusivity provision hereof, upon thirty (30) days' written notice to
Kleen-Tex, in the event that (i) Kleen-Tex fails to meet its [***] label minimum
annual purchase requirement for the preceding calendar year or (ii) Kleen-Tex
fails to use best efforts to promote and market the LaserCode technology in
connection with the Mats.

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

                                       3

<PAGE>

     c. Either party may terminate this Agreement immediately upon written
notice to the other of termination, in the event (i) the other party has
breached any material provision of this Agreement and has failed to cure such
breach within sixty (60) days after receipt of written notice of the breach or
(ii) the other party is the subject of a bankruptcy or insolvency proceeding.

     d. In the event of any termination, the non-breaching party shall have all
remedies available to it at law and equity.

     e. Upon termination, all rights in the LaserCode granted hereunder shall
revert to Spectra.

8. Warranties; Limitations on Liability.

     a. Spectra represents and warrants to Kleen-Tex that it either owns the
LaserCode technology or has obtained and currently holds all rights necessary to
grant the licenses and rights granted to Kleen-Tex hereunder.

     b. SPECTRA MAKES NO OTHER WARRANTY, WHETHER EXPRESS OR IMPLIED, AND
SPECIFICALLY DISCLAIMS ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE. Kleen-Tex is provided the opportunity under this Agreement
to test and evaluate the LaserCode technology and is responsible for determining
the suitability of the same for its business purposes.

     c. Kleen-Tex's sole remedy against Spectra for breach of the foregoing
warranty shall be the refund of any amounts already paid by Kleen-Tex to Spectra
under this Agreement. IN NO EVENT SHALL KLEEN-TEX BE ENTITLED TO ANY SPECIAL,
INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS) OR
DAMAGES EXCEEDING THE AMOUNTS THERETOFORE PAID BY KLEEN-TEX TO SPECTRA UNDER
THIS AGREEMENT.

9. General.

     a. This Agreement shall constitute the entire agreement between the parties
and shall supersede all other prior agreements, oral or written, and all other
communications between the parties relating to the subject matter hereof:

     b. This Agreement shall not be amended except by a writing of subsequent
date hereto, executed by duly authorized representatives of the parties hereto.

     c. This Agreement shall not be assigned by either party without the written
consent of the other party, which consent shall not be unreasonably withheld.

     d. The invalidity or unenforceability of any particular provision of this
Agreement shall not affect the other provisions hereof, and this Agreement shall
be construed in all respects as if such invalid and unenforceable provisions
were omitted.

                                       4

<PAGE>

     e. Neither party shall be liable for failure to perform any obligation
under this Agreement where such failure is due to fire, flood, labor dispute,
war, insurrection, civil unrest, governmental acts, or natural calamities, if
such causes are beyond the reasonable control of such party; provided, however,
that any delay in performance exceeding sixty (60) days shall be grounds for
termination by the non-defaulting party.

     f. This Agreement is made pursuant to and shall be governed by the laws of
the State of Delaware, without regard to its rules regarding conflict of laws.
The parties agree that the courts of the State of Delaware, and the Federal
courts located therein, shall have exclusive jurisdiction over all matters
arising from this Agreement.

                                       5

<PAGE>

IN WITNESS WHEREOF, the parties hereby execute this Agreement through the
representatives listed below:

ACCEPTED AND AGREED TO BY:

Spectra Science Corporation                       Kleen-Tex Industries, Inc.
321 South Main Street                             By-Pass Road
Providence, RI 02903                              LaGrange, Georga 30241

By /s/ Nabil M. Lawandy                           By /s/ Ralph W. Howard
   ----------------------------                      ---------------------------
       Nabil M. Lawandy                                  Ralph W. Howard
       President & CEO                                   President

Date Signed:                                      Date Signed: 4/18/01
             ------------------

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}]]